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Abstract 
Background: GB virus C (GBV-C) is a flavivirus that was characterized in 1995. The prevalence of GBV-C RNA in HIV-
infected subjects has not been previously studied in Iran and was therefore determined.  
Methods: We have investigated serum samples of 80 patients from Imam Khomeini Hospital, Tehran, Iran, whose HIV in-
fection was confirmed in our laboratory by Western-blotting. We used nested-PCR to detect GBV-C/HGV RNA in their sera. 
Results: GBV-C/HGV RNA was detected in 15 (18.8%) of 80 patients. There was no significant difference in GBV-C/HGV RNA 
prevalence between males and females, in different age groups and HIV viral loads groups. 
Conclusion: The prevalence of GBV-C RNA was high in HIV-infected patients. There was no association between GBV-C 
RNA prevalence and specific gender, age, and HIV viral loads groups. 
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Introduction 
GB virus C (GBV-C) is a blood borne flavivirus 
that was first characterized in 1995 (1, 2). Based 
on comparison of genome organization and se-
quence homologies, GBV- C is the most closely 
related human virus to HCV, another member 
of the flaviviridae (2- 4). GBV-C infection has 
association with neither specific disease nor sub-
stantial health risk (5). 
The presence of serum GBV- C indicates viremia, 
whereas the HGV envelope E2 glycoprotein-spe-
cific antibody (E2Ab) is associated with recovery 
(6-16). 
About 1-4% of healthy blood donors have GBV- 
C viremia in their sera (7-9). GBV-C is primar-
ily parenterally or sexually (9). Male to male sex 
has been proposed to be an effective mode of 
transmission of GBV-C (10). However, a verti-
cal transmission route is also likely (9). Consid-
ering that GBV-C is a blood borne virus, its pre-
valence is high in haemodialysis patients (6.8%), 
multiple blood transfusion recipients (24.4%), and 
hemophilia patients (35.2%) (11). Because of com-
mon routes of transmission, GBV- C infection is 
also high in both, HIV and HCV positive pa-
tients (12). Its prevalence is about 14%-45% in 
HIV positive patients and about 24.4% in HCV 
infected individuals (13, 14). 
Actual prevalence of GBV- C varies according 
to the particular population studied. In addition, 
little is known about prevalence of active GBV- 
C infection in HIV-infected individuals in Iran. 
The aim of the present study was to evaluate the 
prevalence of HGV RNA in serum samples of 
HIV positive patients using RT-PCR. We com-
pared the presence of GBV- C viremia with sex, 
age, HIV viral load. For this purpose, we col-
lected sera from patients referred to Imam Kho-
meini Hospital in Tehran, Iran. 
 
Materials and Methods 
Patients 
Eighty patients from Imam Khomeini Hospital, 
Tehran, Iran who had been identified positive for 
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HIV by ELISA and we confirmed their HIV in-
fection by Western blotting involved in this study. 
The patients’ ages were between 5 and 54 yr 
(meanly 34.7 yr), 87.5% male and 12.5% fe-
male. Serum samples were collected and stored 
at -70 °C. 
Information such as age, sex, transmission routs 
were extracted from patient’ files. We were un-
able to follow up eight patients in further analysis. 
 
RNA GBV-C/HGV extraction and cDNA syn-
thesis 
RNA was extracted from 100µl of serum or 
plasma using the Acid Guanidium Isothiocyanate 
Phenol Chloroform method. 10 µl of extracted 
RNA was used for c-DNA synthesis in a final 
volume of 20 µl. cDNA was synthesized by in-
cubation at 42 °C with MMLV reverse transcrip-
tase and random hexamers for 30 min. The cDNA 
was stored at -20 °C for using in nested-PCR 
method. Positive and negative controls were in-
cluded in each run. Positive controls were pro-
vided from Keyvan laboratory and their GBV-C 
genome was sequenced at Seq. Lab Co. Ger-
many. 
Nested-PCR for GBV-C RNA detection: 
Two sets of primers located in 5’ non-coding re-
gion of GBV-C genome were used in nested- PCR. 










For the first PCR round, 10 µl c-DNA was mixed 
with PCR master mixture containing 10 pmol 
Primer (HG1, HG2) 0.6 mM dNTP, 1.5 unit Taq 
DNA polymerase, 5 µl 10x Buffer and 1.5 mM 
Mgcl2 in a final volume of 50 µl for 30 cycles 
(94 °C 0.5 min, 55 °C 1.5 min, 72 °C 1.5 min ). 
For the second PCR round 10µl product from the 
first PCR round was used as template the other 
reagents (except primers: HG3, HG4) were the 
same as that in the first PCR round. The second 
PCR round was 35 cycles (94 °C 0.5 min, 55 
°C 1.5 min, 72 °C 1.5 min). Amplified products 
were separated by agarose gel electrophoresis and 
visualized by ethidium bromide staining (Fig. 1). 
 
Statistical analysis 
For comparing prevalence data between differ-
ent subgroups in the studied population Chi square 
test and Man Whitney test were used. A P< 0.05 
was considered significant. All P values were cal-
culated as two- tailed. 
 
Ethical considerations 
Informed consent was given from all patients in-
volved in the study. 
 
Results 
In 15 of 80 patients, GBV-C RNA was detect-
able therefore; the prevalence of GBV-C carriers 
was 18.8%. In our study, there was no signifi-
cant difference between prevalence of GBV-C 
RNA in different age groups among GBV-C po-
sitive patients and between mean age in GBV-C 
negative and positive groups of HIV positive po-
pulation. 
There was no significant difference in GBV-
C RNA prevalence between male and female pa-
tients. The prevalence was slightly higher in male 
group but it can be because of involving more 
men in our study than women. 
We compared GBV-C prevalence in different HIV 
viral loads and there was no significant difference.  
Transmission routs were compared in GBV-C 
positive group. In 16.7% patients transmission 
rout was sexual and in the other were intrave-
nous drug using. We did not have patients with 
other transmission routs such as blood transmis-
sion or mother to infant in our GBV-C positive 
group (Table1). 
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Fig. 1: Nested-PCR products. A: Ladder, B: Positive control, C: Negative control, I & K:  GBV-C Positive samples, D, E, 
F, G, H & J: GBV-C Negative samples 
 
Table 1: Prevalence of GBV-C RNA according to sex, age groups, HIV transmission routes, and HIV viral load 
 
Groups % (No.) with GBV-C RNA (Total 15) 
% (No.) without GBV-C 
RNA (Total 65) P value 
sex           
male   20.6 (13) 79.4 (50) 
 female   11.1 (1) 88.9 (8) 
0.67 
age (years)           
<10   0 (0) 100 (1) 
 10_20   0 (0) 0 (0) 
 20_30   26.7 (4) 73.3 (11) 
 30_40   18.2 (6) 81.8 (27) 
 40_50   22.2 (4) 77.8 (14) 
 >50   0 (0) 100 (4) 
0.95 
HIV transmission routes         
 intravenous drug use 83.3 35.3   
 heterosexual contact 16.7 35.3 not 
 blood transmission 0 16.7 evaluated 
 mother to infant 0 5.9   
 addict + sexual 0 5.9   
HIV viral load groups         
<1000 9.1 (1) 90.9 (1) 
 1000-9999 17.4 (4) 82.6 (19) 
 10000-99999 23.1 (6) 76.9 (20) 
 >100000 20 (4) 80 (16) 
 
0.43 
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Discussion 
The aim of this study was to evaluate the preva-
lence of GBV-C RNA in serum samples of 
HIV-1 positive patients: 15 of 80 patients were 
viremic (18.8% GBV-C seroprevalence of GBV-C 
virus genome). This finding confirms with the 
previous reports of virus genome prevalence of 
14% to 45% (13, 14). Similar prevalence of GBV-
C viremia among HIV infected patients (19.5% 
and 18.2%) was reported (11, 15). Higher GBV-C 
RNA prevalence was reported by other groups: 
Aster et al. reported 33.3% prevalence of GBV-
C RNA in HIV-infected patients (16). Similar 
prevalence was reported separately as 37% (13, 
17). There is a higher GBV-C prevalence among 
HIV-infected persons in Scotland (51%) (18). 
Such controversy may be a result of different num-
ber of patients involving in these studies and the 
fact that in the study which was conducted in 
Scotland, the most patient’s transmission route 
was homosexuality (male to male transmission) 
which has been demonstrated that GBV-C trans-
mission trough it, is more frequent. In addition, 
it was shown that male to male transmission is 
a very effective rout in HIV transmission (1 in 
10 to 1 in 1,600) and this rate is really notice-
able compared with other HIV transmission routs 
such as heterosexuality (female to male transmis-
sion: 1 in 700 male to female transmission: 1 in 
200), needle sharing (1 in 150), needle stick (1 in 
200) (19). In Iran prevalence of 12.6%, GBV-C 
RNA was reported in haemodialysis patients (20). 
In addition, a low prevalence of HGV exposure 
was found in the dialysis staff (0%) (21). These 
reported results are lower than HGV prevalence 
in HIV-infected individuals in our study. This 
difference is expected because the routes of trans-
mission of HIV and GBV-C are identical. 
The prevalence of GBV-C RNA did not vary 
according to the age groups and sex in our study. 
Although the prevalence was slightly higher in 
male, the difference was not significant and it can 
be a result of involving more men than women in 
our study (63 out of 72). Our results were simi-
lar to those reported by Rey et al., which showed 
no difference in GBV-C RNA prevalence be-
tween male and female and their mean ages were 
similar in GBV-C positive and GBV-C negative 
groups. However, in the GBV-C genome preva-
lence was lower in patients over 50 yr com-
pared to other age groups (13). In our study, 
there were only 4 persons over 50 yr and none 
of them were GBV-C RNA positive. 
There are some studies, which had demon-
strated that HIV-infected persons who were co-
infected with GBV-C had lower HIV viral loads in 
comparison with HIV-infected individuals without 
GBV-C viremia (6, 22, 23) although there are 
some other studies which showed conflicting re-
sults (24-26).  
We suggest that if there is a relation between 
GBV-C infection and HIV viral loads it could 
affect prevalence of GBV-C RNA in different HIV 
viral loads, hence we compared GBV-C preva-
lence in different HIV viral loads groups and there 
was no significant difference. It can be explained 
by the fact that those studies which reported 
lower HIV viral loads in HIV-infected individu-
als with GBV-C viremia, had followed up their 
patients for a period of time, whereas we consid-
ered test-time HIV viral loads only. However, our 
main goal was to evaluate the prevalence of 
GBV-C RNA in HIV infected patients, and HIV-
GBV-C co-infection and their possible interac-
tions were not concerned. 
In our GBV-C positive group, the transmission 
routes were intravenous drug use (83.3%), and 
sexual relationship (16.7%). Rey et al. (13) re-
ported similar findings. Despite this result, it is 
not valid to report these routes as the main GBV-C 
transmission routes in IRAN, because we did not 
have other possible transmission routes such as 
parenterally and mother to infant in our GBV-C 
positive patients, so we were unable to compare 
different transmission routes. 
In conclusion, the prevalence of GBV-C RNA 
was high in HIV infected patients and there was 
no significant difference in GBV-C RNA preva-
lence between age groups, different genders, and 
HIV viral load groups. 
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